KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) EBT (2016 - 2025)

Historic EBT for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $2.2 billion.

  • Abbott Laboratories' EBT rose 1237.11% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 billion, marking a year-over-year increase of 2006.49%. This contributed to the annual value of $7.0 billion for FY2024, which is 523.71% up from last year.
  • According to the latest figures from Q3 2025, Abbott Laboratories' EBT is $2.2 billion, which was up 1237.11% from $2.2 billion recorded in Q2 2025.
  • In the past 5 years, Abbott Laboratories' EBT registered a high of $2.9 billion during Q1 2022, and its lowest value of $1.3 billion during Q4 2022.
  • In the last 5 years, Abbott Laboratories' EBT had a median value of $1.8 billion in 2023 and averaged $1.9 billion.
  • As far as peak fluctuations go, Abbott Laboratories' EBT soared by 22274.88% in 2021, and later crashed by 4568.85% in 2023.
  • Over the past 5 years, Abbott Laboratories' EBT (Quarter) stood at $2.3 billion in 2021, then crashed by 43.27% to $1.3 billion in 2022, then soared by 35.98% to $1.8 billion in 2023, then rose by 13.09% to $2.0 billion in 2024, then increased by 7.39% to $2.2 billion in 2025.
  • Its EBT stands at $2.2 billion for Q3 2025, versus $2.2 billion for Q2 2025 and $1.8 billion for Q1 2025.